New Risk • Jun 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.6m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 6.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Minor Risks Revenue is less than US$5m (AU$6.1m revenue, or US$4.3m). Market cap is less than US$100m (AU$32.5m market cap, or US$23.2m). Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Rob Heard was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Feb 25
Control Bionics Limited to Report First Half, 2026 Results on Feb 26, 2026 Control Bionics Limited announced that they will report first half, 2026 results on Feb 26, 2026 Board Change • Jan 01
High number of new directors Non Executive Chairman Stephen Rix was the last director to join the board, commencing their role in 2025. Announcement • Dec 01
Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 3.25 million. Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 3.25 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 50,000,000
Price\Range: AUD 0.065
Transaction Features: Subsequent Direct Listing Announcement • Oct 23
Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.062278 million. Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.062278 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 8,852,473
Price\Range: AUD 0.035
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 32,874,567
Price\Range: AUD 0.035
Discount Per Security: AUD 0.00175
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 17,195,180
Price\Range: AUD 0.035
Discount Per Security: AUD 0.0021
Transaction Features: Rights Offering Announcement • Oct 21
Control Bionics Limited, Annual General Meeting, Nov 25, 2025 Control Bionics Limited, Annual General Meeting, Nov 25, 2025. Location: at level 11, 66 clarence street, nsw., sydney Australia Announcement • Sep 17
Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.309837 million. Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.309837 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 8,852,473
Price\Range: AUD 0.035
Discount Per Security: AUD 0.00175
Transaction Features: Rights Offering Announcement • Aug 28
Control Bionics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.062278 million. Control Bionics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.062278 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 58,922,220
Price\Range: AUD 0.035
Discount Per Security: AUD 0.00175
Transaction Features: Rights Offering Announcement • Jul 30
Control Bionics Limited to Report Q4, 2025 Results on Jul 31, 2025 Control Bionics Limited announced that they will report Q4, 2025 results on Jul 31, 2025 Announcement • Mar 26
Control Bionics Limited Announces Board Changes Control Bionics Limited announced the appointment of Dr Stephanie Phillips to its Board of Directors, effective immediately. Dr Phillips brings with her over three decades of clinical, academic and leadership experience in anaesthesia and critical care, and is a highly respected figure in the Australian medical community. Dr Phillips (BMed, FRCA, FANZCA, GAICD) is a Consultant Anaesthetist and Clinical Associate Professor at the Australian National University. She has formerly held senior leadership positions at the University of Sydney including Deputy Head of School, and Academic Lead for Education at the Sydney Adventist Hospital Clinical School and was a member of the Academic Boards of both the University and of the Faculty of Medicine. She has been Managing Director of Northern Specialist Anaesthetics Pty Ltd. She was also the Inaugural Chair of the Australian Society of Anaesthetists Science, Prizes, Awards, and Research Committee. Her international training and clinical expertise span paediatric, cardiothoracic and neurosurgical anaesthesia. Her more recent research interests focus on neuromuscular function monitoring during anaesthesia. A veteran of over 10 international medical aid missions, Dr Phillips is deeply committed to improving patient outcomes and reducing anaesthesia-related morbidity. Her strong research background, medical insight and leadership experience will add significant value to Control Bionics as it expands into new markets across assistive communication, rehabilitation and health diagnostics. The Board also announced the resignation of Peter Ford, founder of Control Bionics, from the Board from 31 March 2025. Peter's vision and passion were the driving force behind the creation of Control Bionics. Inspired by a desire to help unlock the potential of brilliant minds like Stephen Hawking, Peter's insight in 1999--that damaged muscles still emit usable electrical signals--led to the development of the NeuroNode and the founding of the Company. Under Peter's guidance, Control Bionics has grown from a visionary idea into a publicly listed company helping people around the world regain their voice and mobility. His legacy is embedded in the DNA of the company, and his impact on the assistive technology sector is profound. While Peter is stepping down from the Board, he remains passionately committed to the success of Control Bionics and continues to be a significant shareholder. Announcement • Feb 26
Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.918088 million. Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.918088 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 42,624,175
Price\Range: AUD 0.045
Transaction Features: Subsequent Direct Listing Announcement • Feb 25
Control Bionics Limited has filed a Follow-on Equity Offering in the amount of AUD 1.918088 million. Control Bionics Limited has filed a Follow-on Equity Offering in the amount of AUD 1.918088 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 42,624,175
Price\Range: AUD 0.045
Transaction Features: Subsequent Direct Listing Announcement • Dec 20
Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.895654 million. Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.895654 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 9,938,489
Price\Range: AUD 0.07
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 12,714,286
Price\Range: AUD 0.07
Discount Per Security: AUD 0.0035
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 4,428,000
Price\Range: AUD 0.07
Transaction Features: Rights Offering Announcement • Oct 22
Control Bionics Limited Appoints Dr. Samuel Straface (Ph.D.) as New Independent Non-Executive Director Control Bionics Limited appointed Dr. Samuel Straface (Ph.D.) as a new independent non-executive director. Sam is an accomplished Neurophysiologist and has held Senior Executive roles in both Australia and the USA including as President/CEO of multiple Medtech businesses. Sam has extensive experience in the development and commercialisation of premium medical devices and services and will complement the skills of the existing Board in delivering NeuroStrip and other new products to the global market. Announcement • Sep 25
Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.15 million. Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.15 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 16,428,571
Price\Range: AUD 0.07
Discount Per Security: AUD 0.0042
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing New Risk • Sep 24
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$14.2m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (104% increase in shares outstanding). Market cap is less than US$10m (AU$14.2m market cap, or US$9.74m). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (AU$5.4m revenue, or US$3.7m). Announcement • Sep 09
Control Bionics Limited, Annual General Meeting, Oct 10, 2024 Control Bionics Limited, Annual General Meeting, Oct 10, 2024. Location: level 11, 66 clarence street, sydney, nsw Australia Reported Earnings • Aug 29
Full year 2024 earnings released: AU$0.037 loss per share (vs AU$0.062 loss in FY 2023) Full year 2024 results: AU$0.037 loss per share. Revenue: AU$6.36m (up 13% from FY 2023). Net loss: AU$5.91m (loss widened 5.0% from FY 2023). Announcement • Aug 21
Control Bionics Limited Announces New US Insurance Code Approved Control Bionics Limited announced the Centers for Medicare & Medicaid Services (CMS) has approved a new Healthcare Common Procedure Coding System (HCPCS) code for the NeuroNode®. This means it now qualifies for a US$4300 reimbursement that wasn't previously available. Highlights: Once this becomes effective on 1 October 2024: It results in a material benefit to the business' operations in the US. Represents a substantial opportunity to build a wholesale distribution model for the US - as part of previously explained `NeuroNode® Only' strategy. Control Bionics and any of its existing US partners can from 1 October 2024 apply for the extra ~USD 4,300 reimbursement for customers covered by Medicare and Medicaid and further seek to have this covered `in-network' with private insurers. This approval marks a significant milestone in enhancing the accessibility and insurance coverage of NeuroNode® for users with impaired speech and motor function in the United States. Announcement • May 18
Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.251526 million. Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.251526 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 29,105,246
Price\Range: AUD 0.043
Discount Per Security: AUD 0.00258
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Board Change • Mar 22
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Rob Heard was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Mar 05
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Rob Heard was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Jan 22
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Rob Heard was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Jan 19
Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.697642 million. Control Bionics Limited has completed a Follow-on Equity Offering in the amount of AUD 1.697642 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 15,515,253
Price\Range: AUD 0.04
Discount Per Security: AUD 0.002
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 26,925,800
Price\Range: AUD 0.04
Discount Per Security: AUD 0.002
Transaction Features: Rights Offering New Risk • Jan 04
New major risk - Revenue and earnings growth Earnings have declined by 27% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 27% per year over the past 5 years. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Market cap is less than US$10m (AU$7.24m market cap, or US$4.86m). Minor Risk Revenue is less than US$5m (AU$5.6m revenue, or US$3.8m). New Risk • Dec 24
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 60% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 27% per year over the past 5 years. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Market cap is less than US$10m (AU$6.37m market cap, or US$4.33m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$1.3m net loss in 3 years). Revenue is less than US$5m (AU$5.6m revenue, or US$3.8m). Board Change • Nov 21
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Rob Heard was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Oct 17
New major risk - Revenue and earnings growth Earnings have declined by 27% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.0m free cash flow). Shares are highly illiquid. Earnings have declined by 27% per year over the past 5 years. Market cap is less than US$10m (AU$6.35m market cap, or US$4.05m). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$1.3m net loss in 3 years). Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (AU$5.6m revenue, or US$3.6m). Board Change • Oct 12
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Rob Heard was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 25
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Rob Heard was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Sep 06
Control Bionics Limited, Annual General Meeting, Oct 10, 2023 Control Bionics Limited, Annual General Meeting, Oct 10, 2023, at 10:30 AUS Eastern Standard Time. Location: University of NSW CBD Campus, Level 7 1, O'Connell St, Sydney, NSW Sydney Australia Agenda: To receive and consider the Company's financial statements and the reports of the Directors and of the Auditor for the year ended 30 June 2023; to consider Remuneration Report; to Re-elect Roger Hawke as a Director; to Re-elect Professor Robert Heard as a Director; to consider Approval of Issue of Options to Managing Director; and to consider other business matters. New Risk • Aug 03
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 13% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.1m free cash flow). Shares are highly illiquid. Earnings have declined by 32% per year over the past 5 years. Market cap is less than US$10m (AU$7.68m market cap, or US$5.01m). Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (AU$5.3m revenue, or US$3.5m). Board Change • Jul 27
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Rob Heard was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Jun 14
Control Bionics Limited Provides Revenue Guidance for the Year Ended 30 June 2023 Control Bionics Limited provided revenue guidance for the year ended 30 June 2023. The revenue for the year ended 30 June 2023 is expected to be approximately $5.3 million, a more than 20% increase in the revenue of $4.4 million for the year ended 30 June 2022. Board Change • Jun 02
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Robert Heard was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • May 05
Control Bionics Limited Announces Directorate Changes The Board of Control Bionics Limited welcomed Professor Robert Heard as a new independent non-executive director. Robert is a distinguished medical practitioner and Professor of Neurology who brings a wealth of relevant knowledge and experience to its Board. Professor Heard replaces Lindsay Phillips, a long-term director of the Company, who is retiring in order to diversify the skill set of the Board and to achieve its goal of having a majority of independent directors. Board Change • Mar 28
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. CEO, MD & Director Jeremy Steele was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 24
First half 2023 earnings released: AU$0.033 loss per share (vs AU$0.037 loss in 1H 2022) First half 2023 results: AU$0.033 loss per share (improved from AU$0.037 loss in 1H 2022). Revenue: AU$2.98m (up 22% from 1H 2022). Net loss: AU$3.00m (loss narrowed 4.1% from 1H 2022). Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Board Change • Jan 09
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non Executive Director Damian Lismore was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Nov 21
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non Executive Director Damian Lismore was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Oct 21
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non Executive Director Damian Lismore was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 
